NSNirmeen Ahmed Sabry

Nirmeen Ahmed Sabry

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nirmeen Ahmed Sabry has a total of 131 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medication reconciliation in clinical practice: a survey of knowledge, attitude, and practices among Egyptian healthcare providers

    by Aya M. AbdelMagid, Nirmeen A. Sabry, Ahmed Abuelhana, Aaron Courtenay, Amani M. Ali

    Background: Patients are at significant risk of harm from unintended medication errors, which remain prevalent and often preventable in healthcare systems, especially in low- and middle-income countries. Medication reconciliation (MedRec) plays a critical role in minimizing these errors by ensuring an accurate and complete medication list throughout patient transitions in the healthcare system. Aim: This study aimed to assess the current status of the MedRec process in Egypt by exploring the knowledge, attitudes, and practices of physicians and pharmacists as key stakeholders in its implementation. Methods: This descriptive, cross-sectional study used a structured, validated, self-administered online questionnaire targeting Egyptian physicians and pharmacists. The questionnaire was distributed via snowball sampling through professional networks and social media. Branching logic was used to tailor questions based on respondents’ familiarity with MedRec and hospital-based practices. Descriptive statistics were used to summarize the responses, while Chi-square and Mann–Whitney U tests were used to assess group differences. Results: Among 272 respondents (182 pharmacists, 90 physicians), representing multiple Egyptian governorates and healthcare sectors (public, private, and military). Among them, 66.9% reported familiarity with MedRec, significantly higher among pharmacists (73.1% vs. 54.4%; p = 0.002). Most respondents (70.2%) rated MedRec as “very valuable” for patient safety, and both groups expressed strong responsibility for its core tasks. Among the 136 hospital-based respondents familiar with MedRec, 79.4% reported institutional implementation. Physicians were more likely than pharmacists to ask patients for their current medication lists (93.8% vs. 76.1%; p = 0.021). Sources of medication history included patient lists or physician documents (74.3%), family interviews (74.3%), medication boxes from home (59.56%), discharge orders (52.2%), and transfer orders from other facilities (33.8%). Conclusion: Continuous education and training programs are required to close knowledge gaps, strengthen MedRec practices, and promote a culture of patient safety in Egypt.

  • The application of continuous nefopam infusion in analgesia and sedation for mechanically ventilated patients in the ICU: Authors' reply

    by Mohammed Gamal Abdelraouf, Samar Farghali Farid, Ahmed Mohammed Mukhtar, Nirmeen Ahmed Sabry

  • Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in Young Children With Chronic HCV Infection

    by Ahmed N. Farrag, Maggie M. Abbassi, Nirmeen A. Sabry, Tim R. Cressey, Philipa Easterbrook, Fatma S. Ebeid, Manal H. El‐Sayed

    Background and Aims: Sofosbuvir (SOF) plus daclatasvir (DCV) is a primary chronic hepatitis C virus (HCV) treatment in low‐ and middle‐income countries. WHO guidelines recommend a half‐adult dose for children (14–25 kg) based on pharmacokinetic modelling, requiring clinical validation. We evaluated the pharmacokinetics, safety, efficacy and acceptability of DCV (30 mg) and SOF (200 mg) in children weighing 14 to < 17 kg and 17–35 kg. Methods: Children (3–13 years; 14–35 kg) with chronic HCV received a daily paediatric formulation of DCV 30 mg and SOF 200 mg for 12 weeks. Intensive steady‐state PK sampling was performed. Efficacy was assessed by sustained virologic response at 12 weeks post‐treatment (SVR12), and adverse events were monitored. Results: Twenty‐three patients were enrolled in two groups: 14 to < 17 kg ( n = 11; median age 5 [3–8] years) and 17–35 kg ( n = 12; median age 7 [5–13] years). For children 14 to < 17 kg, mean (CV%) AUC24 (ng·h/mL) and C maxss (ng/mL) were 14 875 (55) and 1604 (48) for DCV; 2683 (65) and 1562 (69) for SOF; and 10 456 (77) and 1420 (84) for GS‐331007. For children 17–35 kg, values were 11 082 (47) and 1062 (32) for DCV; 2125 (88) and 952 (61) for SOF; and 15 256 (27) and 1606 (46) for GS‐331007. All patients achieved SVR12, with good acceptability and no serious adverse events. Conclusions: For children 14–35 kg with chronic HCV, half the adult dose of DCV (30 mg) and SOF (200 mg) offered comparable exposure, safety, efficacy and acceptability to the adult regimen. Trial Registration: ClinicalTrials.gov identifier: NCT0585451


  • Open Access

    Impact of pharmacist led mobile application on medication adherence and efficacy in chronic kidney disease

    by Shaza Gamal, Ahmad Mohamad Abbas Elseasi, Nirmeen Ahmed Sabry, Samar Farghali Farid

    Medication adherence is crucial for slowing chronic kidney disease (CKD) progression. A specially designed pharmacist-led mobile application, Kidney Health, was evaluated in a single-center, prospective, 3 months, randomized controlled trial (RCT) to assess its impact on medication adherence and efficacy in patients with CKD. 86 patients were randomly assigned to control group, who received standard of care, and app group, who in addition, had access to Kidney Health. The primary outcome was medication adherence measured by simplified medication adherence questionnaire (SMAQ). Other outcomes evaluated included kidney function, blood pressure, and random blood glucose (RBG). The app group showed a significant increase in adherent patients (P < 0.001) and decreased RBG (P = 0.047). Adherent patients increased (P = 0.002) and RBG decreased (P = 0.006) in app group compared to control group at the end of the study. Kidney Health has shown potential for encouraging patients with CKD to adhere to their medication and improving their clinical outcomes. Trial registration: clinicaltrials.gov with ID: NCT05168449, Date of registration: 12/2021 https://clinicaltrials.gov/study/NCT05168449.


  • Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial

    by Mona S. Abdel Monem, Abdulmoneim Adel, Maggie M. Abbassi, Doaa H. Abdelaziz, Mohamed Hassany, Maissa El Raziky, Nirmeen A. Sabry


  • Open Access

    The effectiveness and pharmacoeconomic study of using different corticosteroids in the treatment of hypersensitivity pneumonitis

    by Marwa G. Elhennawy, Yosri Akl, Maggie Abbassi, Nirmeen A. Sabry

    Purpose: Interstitial lung diseases (ILDs) are caused by inflammation and/or fibrosis of alveolar walls resulting in impaired gas exchange. Hypersensitivity pneumonitis (HP) is the third most common type of ILDs. Corticosteroids are the mainstay treatment for HP. The use of intramuscular (IM) betamethasone or intravenous (IV) dexamethasone as weekly pulse doses has shown higher benefit than daily oral prednisolone for HP patients. The aim of this study is to directly compare different corticosteroids in terms of effectiveness and in monetary values and perform an economic evaluation. Methods: One hundred and seven patients were tested for pulmonary function tests (PFTs) and inflammatory markers to assess the treatment effectiveness. A cost-effectiveness analysis (CEA) was performed. ICERs between 3 treatment groups were calculated. Results: Post treatment, Krebs von den Lungen-6 (KL-6) levels significantly improved in betamethasone group from 723.22 ± 218.18 U/ml to 554.48 ± 129.69 U/ml (p = 0.001). A significant improvement in erythrocyte sedimentation rate (ESR) occurred in the dexamethasone group from 56.12 ± 27.97 mm to 30.06 ± 16.04 mm (p = 0.048). A significant improvement in forced expiratory volume (FEV1), forced vital capacity (FVC) and six-minute walk distance (6MWD) was observed within the three treatment groups. A significant improvement in oxygen desaturation percentage (SpO2) occurred within dexamethasone and betamethasone groups. Betamethasone and dexamethasone were found more cost-effective than prednisolone as their ICERs fell in quadrant C. Furthermore, ICER between betamethasone and dexamethasone was performed; a small difference in cost was found compared to the higher benefit of betamethasone. Conclusion: Betamethasone and dexamethasone were found to be more effective than prednisolone in improving the inflammatory reaction and the clinical features of HP patients. Betamethasone was found to be the best intervention in terms of cost against the effect.


  • Effect of Metformin on Oxidative Stress and Left Ventricular Geometry in Nondiabetic Heart Failure Patients: A Randomized Controlled Trial

    by Ahmed M. Kamel, Batool Ismail, Gamal Abdel Hafiz, Nirmeen Sabry, Samar Farid

    Introduction: There is an increasing interest in using metformin in cardiovascular diseases and its potential new roles. Only two randomized controlled trials investigated the effect of metformin in nondiabetic heart failure (HF) patients. However, none of these studies assess the role of metformin in reducing oxidative stress. We hypothesized that metformin might improve oxidative stress and left ventricular remodeling in nondiabetic HF patients with reduced ejection fraction (HFrEF). Methods and Methods: Seventy HFrEF patients (EF 37% ± 8%; median age 66 years) were randomized to metformin (n = 35) or standard of care (SOC) for HF (n = 35) for 6 months in addition to standard therapy. Outcomes included the difference in the change (Δ) in total antioxidant capacity (TAC) and malondialdehyde (MDA), both assessed colorimetrically and left ventricular mass index (LVMI) assessed through transthoracic echocardiography. Results: Compared with the SOC, metformin treatment increased TAC [Δ = 0.12 mmol/L, confidence intervals (95% CIs): 0.03–0.21; P = 0.007]. TAC increased significantly only in the metformin group (0.90 ± 0.08 mmol/L at baseline vs. 1.04 ± 0.99 mmol/L at 6 months, P < 0.05). Metformin therapy preserved LVMI (Δ = −23 g/m2, 95% CI: −42.91 to −4.92; P = 0.014) and reduced fasting plasma glucose (Δ = −6.16, 95% CI: −12.31 to −0.02, P = 0.047) compared with the SOC. Results did not change after adjusting for baseline values. Changes in MDA left ventricular ejection fraction (LVEF) and blood pressure were not significantly different between groups. Conclusion: Metformin treatment in HF patients with reduced LVEF improved TAC and prevented the increase in LVMI compared with the SOC. These effects of metformin warrant further research in HF patients without diabetes to explore the potential benefits of metformin. Trial Registration Number: This protocol was registered in ClinicalTrials.gov under the number NCT05177588.


  • Open Access

    COVID-19 vaccine hesitancy in Egypt: a cross-sectional study

    by May Ahmed Shawki, Ahmed Kamel, Shaza Gamal, Maggie Magdy Abbassi, Samar Farghali Farid, Nirmeen Ahmed Sabry

    Introduction: Coronavirus disease 2019 (COVID-19) vaccine hesitancy is a major problem. This study aimed to determine the factors associated with COVID-19 vaccine acceptance. Methodology: A cross-sectional survey-based study was conducted on a sample of the Egyptian population using an online survey distributed through social media platforms, including Facebook, WhatsApp, and LinkedIn. The questionnaire was composed of five parts: part I describing the research questionnaire and its aim, part II assessing the demographic data, part III assessing knowledge and attitude towards COVID-19 infection, and part IV and V evaluating knowledge regarding COVID-19 vaccines, factors affecting vaccine acceptance and participants’ attitude toward vaccination. Regression models were used to assess factors associated with vaccine acceptability. Results: A total of 24376 responses were included in the statistical analysis. Females represented more than two-thirds of the study sample (70.5%,) and 18-24 years was the most commonly reported age group. Around one-third of the sample were healthcare professionals (HCPs). Only 14.3% of the participants received or registered to receive the vaccine, while 47% refused to be vaccinated. Regression analysis revealed that male gender, secondary education, older age, married or divorced status, presence of comorbidities, and higher level of knowledge regarding the vaccine were significantly associated with high vaccine acceptance. The most important vaccine attributes influencing vaccine selection in the current work were efficacy and safety. Conclusions: Vaccine hesitancy is currently a major challenge. Governments should design educational campaigns that provide trusted data related to vaccine efficacy and safety to encourage vaccination and enhance awareness.


  • Open Access

    The effect of vitamin K4 supplementation on insulin resistance in individuals with type 2 diabetes: a double-blind randomised placebo-controlled clinical trial

    by Amani M. Ali, Maggie M. Abbassi, Nirmeen A. Sabry, May Fawzi, Shrook Mousa

    Purpose: The purpose of this study was to assess the possible clinical effects of vitamin K4 supplementation in individuals with type 2 diabetes namely insulin resistance, glycaemic control, and lipid profile. Methods: This was a prospective randomised double-blind placebo-controlled clinical trial. A total of 106 patients were randomised to receive either 1 mg of vitamin K4 (menadiol diacetate) or placebo for 24 weeks. Results: Ninety patients (n = 45 in each study group) were included in the final analysis. After 24 weeks, homeostatic model assessment of insulin resistance (HOMA-IR) (16.54 ± 7.81 vs. 29.09 ± 36.56, P = 0.027) and fasting serum insulin (FSI) (6.86 ± 3.45 vs. 11.13 ± 12.66 µU/ml, P = 0.032) were significantly lower in the vitamin K group compared to placebo. Additionally, triglycerides (TG) (144.94 ± 50.7 vs. 172.8 ± 101.5 mg/dl, P = 0.031) and very low-density lipoproteins (VLDL) levels (28.9 ± 9.88 vs. 34.6 ± 20.30 mg/dl, P = 0.027) decreased significantly in the vitamin K group after 24 weeks compared to baseline. Moreover, more patients in the vitamin K group (35.6%) had their antidiabetic medication doses reduced after 24 weeks compared to placebo (13.3%, P = 0.029). Conclusion: Vitamin K4 supplementation for 24 weeks is capable of improving insulin resistance and TG levels in individuals with type 2 diabetes. In addition, the improvement in insulin resistance was reflected in the decrease in antidiabetic medication doses. However, it did not affect fasting plasma glucose (FPG) or glycated haemoglobin (HbA1c). Trial registration: The study was registered on clinicaltrials.gov with ID: NCT04285450.


  • Total Antioxidant Capacity and Prediabetes Are Associated with Left Ventricular Geometry in Heart-Failure Patients with Reduced Ejection Fraction: A Cross-Sectional Study

    by Ahmed M. Kamel, Batool Ismail, Gamal Abdel Hafiz, Nirmeen Sabry, Samar Farid

    Introduction: Few studies explored the association between total antioxidant capacity (TAC) and left ventricular (LV) geometry in patients with heart failure and reduced ejection fraction (HFrEF). The current study aimed to assess factors associated with LV geometry in HFrEF patients with particular emphasis on oxidative stress and glycemic status. Methods: A cross-sectional study was conducted from July 2021 to September 2022. All consecutive patients with HFrEF who were stabilized on optimal or maximally tolerated heart failure medications were recruited. Patients were classified into tertiles based on TAC and malondialdehyde for correlation with other parameters. Results: TAC was significantly associated with LV geometry ( P = 0.01), with higher TAC levels observed in patients with normal LV geometry (0.95 ± 0.08) and concentric hypertrophy (1.01 ± 0.14) than in patients with eccentric hypertrophy (EH) (0.90 ± 0.10). There was a significant positive trend in the association between glycemic state and LV geometry ( P = 0.002). TAC showed a statistically significant positive correlation with EF ( r = 0.29, P = 0.0064) and a negative correlation with LV internal diameter at end diastole ( r = −0.26, P = 0.014), LV mass index ( r = −0.25, P = 0.016), and LV mass ( r = −0.27, P = 0.009). After adjusting for multiple confounders, prediabetes [odds ratio (OR) = 4.19, P = 0.032] and diabetes (OR = 7.47, P = 0.008) were associated with higher odds of EH than normoglycemic patients. A significant inverse trend was also observed in the association between TAC tertile and the odds of LV geometry (OR = 0.51, P = 0.046). Conclusions: TAC and prediabetes are significantly associated with LV geometry. TAC can be used as an additional marker in HFrEF patients to reflect the severity of the disease. Interventions aimed at managing oxidative stress might be useful in HFrEF patients to reduce oxidative stress and improve LV geometry and quality of life. Trial Registration Number: This study is part of an ongoing randomized clinical trial ( ClinicalTrials.gov identifier NCT05177588).